Rasburicase

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.5. Supportive medicines

EMLc | ATC codes: V03AF07

Indication	Tumour lysis syndrome ICD11 code: 5D01
INN	Rasburicase
Medicine type	Biological agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 1.5 mg in vial powder and 1 mL solvent for solution ; 7.5 mg in vial powder and 5 mL solvent for solution
EML status history	First added in 2021 (TRS 1035) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer supportive care Cancer
Wikipedia	Rasburicase
DrugBank	Rasburicase

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.